A Phase I Multicenter, Dose Escalation Study of AMN107 in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST).

Trial Profile

A Phase I Multicenter, Dose Escalation Study of AMN107 in Combination With Imatinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST).

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions
  • Acronyms GIST
  • Most Recent Events

    • 12 Mar 2012 Actual patient number changed from 53 to 14 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual patient number changed from 53 to 14 as reported by ClinicalTrials.gov.
    • 13 Feb 2012 Actual number of patient changed from 53 to 59 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top